Bionano Genomics, Inc. (BNGO)Healthcare | Medical Instruments & Supplies | San Diego, United States | NasdaqCM
1.17 USD
-0.04
(-3.306%) ⇩
(Aug. 28, 2026, 4 p.m.
EDT)
After hours: 1.17 |
Hot Take ↕ | Aug. 22, 2026, 4:55 a.m. EDT
The immediate outlook remains flat due to a lack of clear directional momentum, though the stock has recently stabilized near its 52-week lows after a catastrophic multi-year decline. The long-term investment case is effectively broken; the business has suffered a nearly 99.9% loss of value over the last seven years, with four consecutive years of negative annual returns ending in a sharp drop. Despite the 'strong buy' analyst consensus and a theoretical target price of $5, these metrics are disconnected from the reality of a company with negative earnings, negative operating cash flow, and a massive gap between its book value and trading price. The market has already priced in the failure of the underlying business model, rendering any 'value' argument moot given the structural deterioration. There is no dividend to provide income, and the statistical models offer no reliable short-term edge, leaving the security as a speculative trap rather than an opportunity. |
| Model | MAE |
|---|---|
| MSTL ✓ | 0.078270 |
| AutoARIMA | 0.078709 |
| AutoETS | 0.078710 |
| AutoTheta | 0.094495 |
Forecast horizon: 45 days | Selected: MSTL
| Forecast Reliability | |
|---|---|
| Score | 39% |
| H-stat | 3.53 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.019 |
| Excess Kurtosis | 1.34 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 21.211 |
| Revenue per Share | 3.162 |
| Market Cap | 13,779,089 |
| Forward P/E | -1.21 |
| Beta | 1.62 |
| Profit Margins | -106.58% |
| Website | https://bionano.com |
| Attribute | Value |
|---|---|
| 52 Week Change | -0.7041565 |
| Address1 | 9,540 Towne Centre Drive |
| Address2 | Suite 100 |
| All Time High | 9,414.0 |
| All Time Low | 1.0 |
| Ask | 1.48 |
| Ask Size | 2 |
| Audit Risk | 8 |
| Average Daily Volume10 Day | 151,090 |
| Average Daily Volume3 Month | 134,174 |
| Average Volume | 134,174 |
| Average Volume10Days | 151,090 |
| Beta | 1.617 |
| Bid | 0.8784 |
| Bid Size | 2 |
| Board Risk | 9 |
| Book Value | 2.684 |
| City | San Diego |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Compensation Risk | 8 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 1.17 |
| Current Ratio | 2.478 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,786,665,600 |
| Day High | 1.24 |
| Day Low | 1.16 |
| Debt To Equity | 21.211 |
| Display Name | Bionano Genomics |
| Earnings Call Timestamp End | 1,786,393,800 |
| Earnings Call Timestamp Start | 1,786,393,800 |
| Earnings Timestamp | 1,786,392,000 |
| Earnings Timestamp End | 1,794,513,600 |
| Earnings Timestamp Start | 1,794,513,600 |
| Ebitda | -22,873,000 |
| Ebitda Margins | -0.75799006 |
| Enterprise To Ebitda | -0.462 |
| Enterprise To Revenue | 0.35 |
| Enterprise Value | 10,564,090 |
| Eps Current Year | -2.14 |
| Eps Forward | -0.97 |
| Eps Trailing Twelve Months | -2.89 |
| Esg Populated | 0 |
| Exchange | NCM |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 1.1514 |
| Fifty Day Average Change | 0.018599987 |
| Fifty Day Average Change Percent | 0.016154235 |
| Fifty Two Week Change Percent | -70.41565 |
| Fifty Two Week High | 5.5 |
| Fifty Two Week High Change | -4.33 |
| Fifty Two Week High Change Percent | -0.7872727 |
| Fifty Two Week Low | 1.0 |
| Fifty Two Week Low Change | 0.16999996 |
| Fifty Two Week Low Change Percent | 0.16999996 |
| Fifty Two Week Range | 1.0 - 5.5 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,534,858,200,000 |
| Float Shares | 10,640,520 |
| Forward Eps | -0.97 |
| Forward P E | -1.2061855 |
| Free Cashflow | 2,347,750 |
| Full Exchange Name | NasdaqCM |
| Full Time Employees | 95 |
| Fullday Change | -0.0400001 |
| Fullday Change Percent | -3.30579 |
| Fullday Price | 1.17 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Governance Epoch Date | 1,785,542,400 |
| Gross Margins | 0.47505 |
| Gross Profits | 14,335,000 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.07218 |
| Held Percent Institutions | 0.0849 |
| Implied Shares Outstanding | 11,777,000 |
| Industry | Medical Instruments & Supplies |
| Industry Disp | Medical Instruments & Supplies |
| Industry Key | medical-instruments-supplies |
| Is Earnings Date Estimate | 0 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Last Split Date | 1,737,936,000 |
| Last Split Factor | 1:60 |
| Long Business Summary | Bionano Genomics, Inc., together with its subsidiaries, provides genome analysis solutions in the Americas, Europe, the Middle East, Africa, China, Japan, South Korea, Singapore, India, and Australia. The company offers genome analysis software that enables genomics labs to analyze and interpret data across a range of platforms to generate informative data visualizations for streamlined and simple reporting of causal variants. It also provides Saphyr and Stratys systems, which are sample-to-result solutions for structural variation analysis by optical genome mapping for genome analysis and understanding of genetic variation and function; Saphyr and Stratys instruments, which are single-molecule imagers; Saphyr Chip, a consumable that packages the nanochannel arrays for DNA linearization; Bionano Prep Kits and DNA labeling kits, which provide the reagents and protocols for extracting and labeling ultra-high molecular weight DNA; and Ionic purification system, which isolates and purifies nucleic acid molecules. In addition, the company offers Saphyr, Stratys, and Bionano compute servers; and VIA software, which offers one solution for solutions for cytogenetics and molecular genetics. Further, it provides testing and laboratory services comprising FirstStepDx PLUS, a chromosomal microarray for identifying an underlying genetic cause in individuals with autism spectrum disorder, developmental delay, and intellectual disability; Fragile X syndrome (FXS) testing services; NextStepDx PLUS, a exome sequencing test to identify genetic variants that are associated with disorders of childhood development; OGM-Dx HemeOne testing; OGM-Dx FSHD, a test for individuals suspected of having FSHD type 1; and OGM-Dx Postnatal Whole Genome SV and OGM-Dx Prenatal Whole Genome SV for comprehensive testing. Bionano Genomics, Inc. was founded in 2003 and is headquartered in San Diego, California. |
| Long Name | Bionano Genomics, Inc. |
| Market | us_market |
| Market Cap | 13,779,089 |
| Market State | CLOSED |
| Max Age | 86,400 |
| Message Board Id | finmb_5900432 |
| Most Recent Quarter | 1,782,777,600 |
| Net Income To Common | -32,163,000 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 14,367,940 |
| Number Of Analyst Opinions | 2 |
| Open | 1.23 |
| Operating Cashflow | -20,480,000 |
| Operating Margins | -0.88337 |
| Overall Risk | 9 |
| Payout Ratio | 0.0 |
| Phone | 858 888 7600 |
| Post Market Change | 0.0 |
| Post Market Change Percent | 0.0 |
| Post Market Price | 1.17 |
| Post Market Time | 1,787,959,804 |
| Previous Close | 1.21 |
| Price Eps Current Year | -0.5467289 |
| Price Hint | 4 |
| Price To Book | 0.4359165 |
| Price To Sales Trailing12 Months | 0.4566241 |
| Profit Margins | -1.06585 |
| Quick Ratio | 1.423 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | none |
| Region | US |
| Regular Market Change | -0.0400001 |
| Regular Market Change Percent | -3.30579 |
| Regular Market Day High | 1.24 |
| Regular Market Day Low | 1.16 |
| Regular Market Day Range | 1.16 - 1.24 |
| Regular Market Open | 1.23 |
| Regular Market Previous Close | 1.21 |
| Regular Market Price | 1.17 |
| Regular Market Time | 1,787,947,201 |
| Regular Market Volume | 179,511 |
| Return On Assets | -0.32556 |
| Return On Equity | -0.83562 |
| Revenue Growth | 0.214 |
| Revenue Per Share | 3.162 |
| Sand P52 Week Change | 0.20504117 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Share Holder Rights Risk | 8 |
| Shares Outstanding | 11,777,000 |
| Shares Percent Shares Out | 0.098000005 |
| Shares Short | 1,153,598 |
| Shares Short Previous Month Date | 1,784,073,600 |
| Shares Short Prior Month | 1,086,325 |
| Short Name | Bionano Genomics, Inc. |
| Short Percent Of Float | 0.098000005 |
| Short Ratio | 10.41 |
| Source Interval | 15 |
| State | CA |
| Symbol | BNGO |
| Target High Price | 6.0 |
| Target Low Price | 4.0 |
| Target Mean Price | 5.0 |
| Target Median Price | 5.0 |
| Total Cash | 9,919,000 |
| Total Cash Per Share | 0.842 |
| Total Debt | 6,704,000 |
| Total Revenue | 30,176,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -2.89 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 1.2901 |
| Two Hundred Day Average Change | -0.12010002 |
| Two Hundred Day Average Change Percent | -0.093093574 |
| Type Disp | Equity |
| Volume | 179,511 |
| Website | https://bionano.com |
| Zip | 92,121 |